58644
document
Effect of perioperative parecoxib on postoperative pain and local inflammation factors PGE2 and IL-6 for total knee arthroplasty : a randomized , double-blind , placebo-controlled study . To assess the efficacy of postoperative pain management and the concentration change of PGE-2 and IL-6 of joint fluid with parecoxib after postoperative total knee arthroplasty . In the study , 100 patients experiencing primary TKA were randomly divided into study group , receiving parecoxib sodium ( 40 mg ) intravenously ( IV ) at the completion of surgery and once every 12 h for totally 6 times postoperatively , and placebo group , receiving normal saline 2 mL IV at the same time points . Efficacy was assessed by total amount of morphine consumed , pain intensity , range of motion ( ROM ) , the concentration change of PGE-2 and IL-6 of joint fluid , and postoperative nausea and vomiting ( PONV ) postoperatively . Patients in study group consumed significantly less morphine , experienced significant less pain scores , and obtained significantly more ROM ( P < 0.01 ) compared with that in placebo group during 3 days postoperatively . The concentration of PGE-2 and IL-6 of joint fluid in study group are significantly lower than that in placebo group ( P < 0.01 ) during 24 h postoperatively . The overall incidence of PONV was low and was not significantly different between the two groups . The present study demonstrated that the perioperative administration of parecoxib after primary TKA resulted in significantly improved postoperative analgesic management as defined by reduction in opioid requirement , lower pain scores and ROM , and significantly lowered local inflammation factors PGE2 and IL-6 .
58645
Intervention_Pharmacological
parecoxib
58646
Intervention_Control
placebo-controlled
58647
Intervention_Pharmacological
parecoxib
58648
Intervention_Pharmacological
parecoxib sodium
58649
Outcome_Pain
postoperative pain and local inflammation
58650
Outcome_Other
efficacy
58651
Participant_Sample-size
100
58652
Participant_Condition
primary TKA